Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist

in portfolio news

Rigontec, the leader in RIG-I
targeting RNA therapeutics, today announced the dosing of the first patient in a phase I/II
study with intratumoral/intralesional administration of its lead compound RGT100 in solid
tumors and lymphoma. RGT100 targets the retinoic acid-inducible gene I (RIG-I) pathway,
one of the most essential pathways in the innate immune system to induce both immediate
and long-term anti-tumor immunity. Targeting RIG-I is a novel and distinct approach in
cancer immuno-therapy which has demonstrated substantial local and systemic tumor
regression in several relevant in vivo models. Rigontec has been spearheading efforts to
access this pathway to develop new treatment options and this study will be the first to test
the approach in patients.